The FDA was expected to decide on the application of sotorasib and panitumumab for the treatment of metastatic colorectal ...

U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, ...

The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic ...

The Federal Trade Commission (FTC) and the Department of Justice (DOJ) have released the 2023 Hart-Scott-Rodino (HSR) Annual ...

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

At the STAT summit, executives discuss their challenges, and hopeful signals, about breaking into markets on obesity and ...

An investor is suing Amgen Inc.'s leaders over the company’s $10.7 billion fight with the IRS, which has said the ...

A first-in-class anti-CD19 B-cell depleting agent was safe and demonstrated superior efficacy vs placebo in patients with ...

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

On Tuesday, Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $325.09 which represents a slight increase of $0.47 or 0.14% from the prior close of $324.62. The stock opened at $326.03 and ...

Patients with inflammatory bowel disease (IBD) who initially responded to the investigational monoclonal antibody ...